National Comprehensive Cancer Network

NCCN Oncology Research Program (ORP)
ORP Recent News
ORP Affiliate Research Consortium
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
NCCN Shared Resources (Members Only
ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

Trastuzumab added to NCCN Drugs & Biologics Compendium™ for Gastric Cancer

The Gastric Cancer chapter of the NCCN Drugs and Biologics Compendium™ now includes a recommendation for trastuzumab to be used in combination with systemic chemotherapy for the treatment of patients with advanced gastric cancer that is HER-2 positive as determined by a standardized method.

Van Cutsem, et. al. presented data from a phase III trial of 594 patients with HER-2 positive advanced gastric cancer at ASCO in June 2009. Patients were randomized to receive chemotherapy with or without trastuzumab. Overall survival in patients randomized to receive trastuzumab with chemotherapy was significantly (13.8 vs 11.1 months, p=0.0048) greater than with chemotherapy alone. Secondary efficacy parameters were also significantly improved.

This NCCN recommendation is based on deliberations of the NCCN Clinical Practice Guidelines in Oncology™ Gastric Cancer Panel. The recommendation is a Category 2A Recommendation according to the NCCN categories of evidence and consensus.